Table 1 Patient, tumor, and therapy characteristics. All values are presented as median (range) or percentage (count) of subgroup
Total cohort (n = 144) | Responders (n = 120) | Non-responders (n = 24) | |
|---|---|---|---|
Age (years) | 60 (32–80) | 61 (33–80) | 52 (32–79) |
BMI (kg/m2) | 25.1 (16.0–42.0)d | 25.2 (16.0–42.0) | 24.2 (19.7–34.6) |
Smoker | 14.0% (n = 20) | 11.8% (n = 14) | 25.0% (n = 6) |
Radiological tumor extent (mm) | 20 (5–60) | 20 (5–60) | 25 (6–60) |
Histological tumor extent (mm) | 23 (6–90) | 22 (6–90) | 25 (10–51) |
Specimen weight (g) | 86 (14–345)e | 92 (14–345) | 62 (33–161) |
Breast volume (cm3)a | 644 (110–2033)f | 644 (110–2033) | 637 (200–1395) |
EPBVE (%)b | 14 (3–35)g | 15 (3–35) | 13 (7–28) |
Oncoplastic method | |||
Raquet | 49.3% (n = 71) | 54.2% (n = 65) | 25.0% (n = 6) |
Round block | 21.5% (n = 31) | 20.0% (n = 24) | 29.2% (n = 7) |
V-mammoplasty | 13.2% (n = 19) | 10.8% (n = 13) | 25.0% (n = 6) |
Inverted-T | 7.6% (n = 11) | 7.5% (n = 9) | 8.3% (n = 2) |
J-mammoplasty | 6.9% (n = 10) | 6.7% (n = 8) | 8.3% (n = 2) |
Other | 1.4% (n = 2) | 0.8% (n = 1) | 4.2% (n = 1) |
Axillary clearance | 27.8% (n = 40) | 30.0% (n = 36) | 16.7% (n = 4) |
Re-excision | 4.9% (n = 7) | 4.2% (n = 5) | 8.3% (n = 2) |
Postoperative complications of the breastc | |||
Grade 1 | 2.1% (n = 3) | 2.5% (n = 3) | 0 |
Grade 2 | 2.1% (n = 3) | 0.8% (n = 1) | 8.3% (n = 2) |
Grade 3 | 1.4% (n = 2) | 1.7% (n = 2) | 0 |
Neoadjuvant chemotherapy | 17.4% (n = 25) | 17.5% (n = 21) | 16.7% (n = 4) |
Adjuvant chemotherapy | 25.0% (n = 36) | 26.7% (n = 32) | 16.7% (n = 4) |
Adjuvant endocrine therapy | 72.2% (n = 104) | 74.2% (n = 89) | 62.5% (n = 15) |
Postoperative radiotherapy | 100% (n = 144) | 100% (n = 120) | 100% (n = 24) |
Breast density | |||
High (BI-RADS® C–D) | 30.6% (n = 55) | 54.2% (n = 13) | 35.0% (n = 42) |
Low (BI-RADS® A–B) | 62.5% (n = 89) | 45.8% (n = 11) | 65.0% (n = 78) |
Follow-up time (months) | 27 (15–54) | 28 (15–54) | 24 (15–54) |